TABLE 2.
Treatments, disease course and outcome of COVID-19 patients after admission to the general ward
| Age decade | p-value | ||||
| <50 years (n=89) | ≥50– <60 years (n=111) | ≥60– <70 years (n=135) | ≥70 years (n=129) | ||
| Treatment | |||||
| Supplementary oxygen therapy | 84 (94.4) | 107 (96.4) | 131 (97.0) | 125 (96.9) | 0.737 |
| High-flow nasal cannula | 2 (2.2) | 8 (7.2) | 19 (14.1) | 17 (13.2) | 0.012 |
| Noninvasive ventilation | 1 (1.1) | 0 (0.0) | 3 (2.2) | 8 (6.2) | 0.015 |
| Invasive ventilation | 8 (9.0) | 10 (9.0) | 22 (16.3) | 9 (7.0) | 0.073 |
| Remdesivir | 12 (13.5) | 10 (9.0) | 14 (10.4) | 17 (13.2) | 0.670 |
| Chloroquine | 0 (0.0) | 2 (1.8) | 0 (0.0) | 1 (0.8) | 0.284 |
| Monoclonal antibodies against SARS-CoV-2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.8) | 0.457 |
| Antibiotics in the first 7 days of admission | 31 (34.8) | 40 (36.0) | 70 (51.9) | 65 (50.4) | 0.010 |
| Immunomodulating therapies | |||||
| Dexamethasone 6 mg | 72 (80.9) | 89 (80.2) | 102 (75.6) | 103 (79.8) | 0.730 |
| Of which before sampling | 62 (69.7) | 79 (71.2) | 96 (71.1) | 93 (72.1) | 0.985 |
| Other corticosteroids# | 4 (4.5) | 3 (2.7) | 6 (4.4) | 3 (2.3) | 0.713 |
| Of which before sampling | 3 (3.4) | 2 (1.8) | 5 (3.7) | 1 (0.8) | 0.392 |
| Interleukin-6 inhibitors | 10 (11.2) | 11 (9.9) | 13 (9.6) | 12 (9.3) | 0.971 |
| Of which before sampling | 4 (4.5) | 1 (0.9) | 3 (2.2) | 3 (2.3) | 0.426 |
| Anti-C5a antibody | 0 (0.0) | 0 (0.0) | 1 (0.7) | 1 (0.8) | 0.677 |
| Of which before sampling | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | >1.000 |
| Imatinib | 1 (1.1) | 5 (4.5) | 3 (2.2) | 11 (8.5) | 0.027 |
| Of which before sampling | 0 (0.0) | 1 (0.9) | 2 (1.5) | 4 (3.1) | 0.279 |
| Clinical course | |||||
| Thrombosis | 5 (5.6) | 12 (10.8) | 9 (6.7) | 18 (14.0) | 0.110 |
| Of which pulmonary embolism¶ | 5 (5.6) | 10 (9.0) | 9 (6.7) | 17 (13.2) | 0.175 |
| Of which deep venous thrombosis¶ | 0 (0.0) | 4 (3.6) | 0 (0.0) | 2 (1.6) | 0.054 |
| Length of hospital stay, days | 4 (2–7) | 4 (3–8) | 6 (3–11) | 7 (4–11) | <0.001 |
| ICU admission+ | 9 (10.1) | 15 (13.5) | 26 (19.3) | 13 (10.1) | 0.113 |
| ICU stay, days | 15 (8–29) | 11 (9–13) | 8 (5–14) | 8 (1–17) | 0.450 |
| Readmission§ | 4 (4.5) | 5 (4.5) | 6 (4.4) | 10 (7.8) | 0.581 |
| Mortalityƒ | |||||
| 30-day | 1 (1.1) | 2 (1.8) | 16 (11.9) | 39 (30.2) | <0.001 |
| 90-day | 2 (2.2) | 2 (1.8) | 16 (11.9) | 43 (33.3) | <0.001 |
Data are presented as median (interquartile range) or n (%), unless otherwise stated. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; ICU: intensive care unit. #: prednisolone and hydrocortisone; ¶: numbers do not add up to 100% as some patients suffered from both pulmonary embolism and deep venous thrombosis; +: ICU admission after sampling; §: for any cause within 28 days of the initial admission; ƒ: for 98.2% of patients, worsening of COVID-19 was reported as a causal element for mortality by the treating physician.